EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care DA VINCI

EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care DA VINCI - DA VINCI

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012884

Enrollment

6000

Registered

2017-10-17

Start date

2017-11-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipid-Modifying Therapy

Interventions

Group 1: This is an observational study. All patients will be observed as one group. Therefore the methodology description for this research is a case note review, cross-sectional study with a questio

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion Criteria • LDL-C measurement within 14 months of enrolment, obtained independently of participation in a clinical trial • Use of any LMT (may include statin/ezetimibe/fibrate/PCSK9 inhibitor/bile acid absorption inhibitor/nicotinic acid/other) at time of enrolment, or any LMT prescribed within 12 months prior to date of enrolment, or any LMT prescribed at date of enrolment • Age = 18 years at enrolment • Provided informed consent/notified according to local requirements • Subject expected to survive for at least 1 year after enrolment

Exclusion criteria

Exclusion criteria: Exclusion Criteria • Diagnosis of FH and with history of CV event • Currently receiving therapy for carcinoma (excepting squamous epithelial cell) • Known HIV positive status • Pregnant or breastfeeding at time of enrolment • Participating in an interventional clinical trial within 6 months prior to enrolment

Design outcomes

Primary

Measure	Time frame
LDL-C measurement most recent to enrolment (within previous 14 months)	—

Secondary

Measure	Time frame
Secondary outcome measure: • Lipid levels (total cholesterol, non-HDL-C, HDL, triglycerides, Lp(a), apo B100, apo A1) most recent to enrolment (within previous 14 months) • Use of LMT (type, dose, frequency) including combination therapy, in 12 months prior to enrolment, up to and including enrolment date • Clinical characteristics at time of enrolment as assessed in relation to: - FH status (diagnosed/ not diagnosed) - CV history - Diabetic status (diabetic/not diabetic; Type 1 or Type II) - CKD status	—

Measure

Time frame

Secondary outcome measure: • Lipid levels (total cholesterol, non-HDL-C, HDL, triglycerides, Lp(a), apo B100, apo A1) most recent to enrolment (within previous 14 months) • Use of LMT (type, dose, frequency) including combination therapy, in 12 months prior to enrolment, up to and including enrolment date • Clinical characteristics at time of enrolment as assessed in relation to: - FH status (diagnosed/ not diagnosed) - CV history - Diabetic status (diabetic/not diabetic; Type 1 or Type II) - CKD status

—

Countries

Austria, Belgium, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Poland, Romania, Slovakia, Spain, Sweden, Ukraine, United Kingdom

Contacts

Public ContactJohanna Sukumar

Imperial College London

j.sukumar@imperial.ac.uk+44 (0) 207 594 2594

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026